Admitting defeat in pharma R&D and terminating a failing project is a hard decision to make – and sometimes companies file for an Investigational New Drug (IND) application despite unpromising data. Why? A group of researchers recently asked this very question and decided to publish an article on the subject to highlight the issue (1). We spoke to one of the authors, Dennis Lendrem, translational research project manager at the University of Newcastle’s Institute of Cellular Medicine, about the problems facing R&D.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
References
- Richard W. Peck et al., Nature Reviews Drug Discovery, doi:10.1038/nrd4725 (2015). Dennis Lendrem et al., Pharm Stat., 14(1), 1-3 (2014).
